Clinica BavieraXMAD:CBAV +1.37%100 Return-on-Tangible-Equity is 76.66% as of Mar. 2026, which is 5% above its 10-year median of 72.69. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.36 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 81.77% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Clinica Baviera's annualized net income for the quarter that ended in Mar. 2026 was €58.8 Mil. Clinica Baviera's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €76.7 Mil. Therefore, Clinica Baviera's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 76.66%.
The historical rank and industry rank for Clinica Baviera's Return-on-Tangible-Equity or its related term are showing as below:
XMAD:CBAV'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 57.14 Med: 72.69 Max: 122.16
Current: 65.48
During the past 13 years, Clinica Baviera's highest Return-on-Tangible-Equity was 122.16%. The lowest was 57.14%. And the median was 72.69%.
XMAD:CBAV's Return-on-Tangible-Equity is ranked better than 81.77% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405
vs XMAD:CBAV: 65.48
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Clinica Baviera Return-on-Tangible-Equity Related Terms
Clinica Baviera Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:CBAV vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 76.66% mean?
Clinica Baviera (XMAD:CBAV) has a Return-on-Tangible-Equity of 76.66% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Clinica Baviera and its competitors. This is near median its historical median of 72.69. Over the past decade, Clinica Baviera's Return-on-Tangible-Equity has ranged from 57.14 to 122.16. According to the industry distribution chart, Clinica Baviera ranks #35 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 18.2%.
Is Clinica Baviera's Return-on-Tangible-Equity too high?
Clinica Baviera's current Return-on-Tangible-Equity of 76.66% is near median its 10-year median of 72.69. Over the past 10 years, this metric has ranged from a low of 57.14 to a high of 122.16. Based on the distribution chart, Clinica Baviera ranks #35 out of 192 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #35 out of 192 companies for Return-on-Tangible-Equity. This places Clinica Baviera in the top 18% of its industry — outperforming the majority of peers. Historically, Clinica Baviera's own Return-on-Tangible-Equity has ranged from 57.14 to 122.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Clinica Baviera and its competitors. Clinica Baviera's current Return-on-Tangible-Equity is 76.66%, which is near median its own 10-year median of 72.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.36, compared to a current price of €59.40 — trading 43.6% above its estimated fair value. The current Return-on-Tangible-Equity is 76.66%, which is near median its 10-year median of 72.69. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Return-on-Tangible-Equity is 76.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €59.40 is trading 43.6% above its estimated GF Value™ of €41.36.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
Return-on-Tangible-Equity: 76.66% (near median its 10-year median of 72.69)
GF Value™: €41.36 vs. price of €59.40 (43.6% above fair value)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
